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Last year three different groups led by Feng Zhang1 at the
Broad Institute, George Church2 at Harvard Medical School,
Jin-Soo Kim3 at Seoul National University and Jennifer
Doudna4 at the University of California Berkeley, have
adapted the prokaryotic immunity component, Clustered,
Regularly Interspaced, Short Palindromic Repeats (CRISPR),
to achieve genome engineering in mammalian cells. The
impact of this approach was immediate; within a few months,
several scientific reports have implemented or adapted this
technique, highlighting its potential power. How effective is
this new technology and will it render obsolete classical RNA
interference and conventional in vivo mouse knockout
strategies? And importantly, will it have an impact on the lives
of the non-scientific population, such as by accelerating the
generation of genetically modified foodstuffs and opening the
possibility to correct and cure human genetic diseases?
Effective genome-editing systems are the Holy Grail for
molecular biologists although the methods currently in use
appear cumbersome by comparison with the CRISPR
technology. CRISPR has only been developed as a result of
the continued interest of biologists in elementary organisms,
and the identification in prokaryotes of an innovative tool with
which to modify the mammalian genome.
CRISPR is a natural RNA-guided DNA nuclease system
used by archaea and bacteria to protect against invasive
phage or plasmid DNAs. The CRISPR system is genomically
encoded by the prokaryotic chromosome and includes a
variable number of short repeats separated by non-repetitive
spacer sequences, which are derived from previously
encountered foreign DNAs. These spacers can match
‘proto-spacer’ sequences of invasive DNAs, functioning as a
genomically recorded immunological memory. This region is
flanked by a ‘leader’ sequence and by cas genes. The cas
genes encode the protein component of the interference
machinery. In the active machinery, the Cas protein loaded
with the mature CRISPR RNA (crRNA) is delivered to the
target DNA by double-strand base pair complementarity, and
the CRISPR-associated nucleases cleave the invader nucleic
acid (Figure 1a).5 The Cas9 protein, a type II CRISPR-
associated Cas, exerts an endonuclease function by causing
double-strand breaks (DSBs) in DNA. Exploiting the Cas9’s
activity and designing crRNA (also named guide RNAs,
gRNA) to target mammalian genome sequences, Zhang,
Church, Kim and Doudna have developed a method to
surgically operate on any genomic region. Transfection of
mammalian expression vectors containing CRISP compo-
nents, including a nuclear-localized Cas9 protein, resulted in
the disruption of intended target genes in different cell lines.
Cas9-dependent DSBs were generated at the designed loci
and consequent activation of the mutagenic non-homologous
end joining (NHEJ) machinery finalized gene disruption with
reasonable efficiency (Figure 1b).
What about specificity and off-targets effects? One of the
major limitations of the widely used genome-editing technol-
ogies based on transcription activator-like effector nucleases
(TALENs) and zinc finger nucleases (ZNFs) is their off-target
effects.6,7 Homologous recombination minimizes off-target
effects of CRISPR. A mutant form of Cas9 (a nickase
endonuclease), generating only DNA single-strand breaks,
yielded similar homologous recombination but a lower NHEJ
rate, thus reducing the NHEJ-dependent insertions, deletions
and chromosomal rearrangements. Most of the potential of
CRISPR indeed lies in the flexibility of the Cas9 protein. On
the other hand, the possibility to design gRNAs for every
genomic locus boosts the potential of this technology. With a
catalytically active Cas9 protein, the CRISPR approach can
generate gene disruption, whereas a defective Cas9 (dCas9)
can either enable or disable the expression of a defined gene.
Coupling dCas9 with a transcriptional activator or repressor
has made possible the manipulation of specific gene
transcription without altering genomic sequences.8 A system,
called CRISPRi, employs a dCas9 lacking endonuclease
activity that, when coexpressed with a gRNA, generates a
DNA recognition complex that can specifically interfere with
transcriptional elongation, RNA polymerase binding or
transcription factor binding (Figure 1c).9 However, the
genomic-editing power of CRISPR goes beyond gene
disruption. The cellular homologous recombinationmachinery
can replace the DNA locus with an engineered donor DNA
fragment, containing a region with homology to the DSB site.
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This method enables the opportunity to integrate external DNA
sequences into the genome. In addition, by adapting CRISPR
as an imaging tool it acquires the potential to significantly
improve the capacity to study genomic loci in live human cells.
Thus, using an EGFP-tagged endonuclease-deficient Cas9
protein and an optimized sgRNA, the Huang group reported
effective imaging of repetitive elements in telomeres and
coding genes in living cells (Figure 1c).10 Now, the inventors of
CRISPR-Cas9, Zhang group, have adapted their method in a
genome-wide knockout screen of human cells. Using lenti-
CRISPR, they have targeted 18 080 genes in melanoma and
embryonic stem cells, and cell with a library of 64 751 unique
gRNAs.11,12 However, as for all the possible applications,
being a particular new technology the limitations of
CRISPR usage in this approach are still under careful
assessment.
Heritable gene targeting in themouse and rat has also been
achieved by the CRIPSPR system. The generation of a
double-gene knockout rat was obtained with a single
microinjection, and the germline-transmission efficiency was
reasonably high in both mice and rats.13 In plants, CRISPR
has been shown to effectively inactivate multiple genes in rice
and wheat.14 This application in plants has the potential, for
example, to confer resistance to parasitic organisms.
CRISPR allows the possibility to knockout genes in cells, to
easily alter simultaneously multiple genes to study their
interactions, and to create animal models much more quickly
than before. The opportunity to precisely and selectively
manipulate genomes is potentially opening a new era in
genetic engineering. The cost- and time-efficiency of this
technology compared with previous methods should boost its
diffusion not only throughout basic science, but also in
Figure 1 (a) CRISPR loci are included in the prokaryotic chromosome. A variable number of repeats are separated by spacer sequences, which derive from previously
encountered nucleic acids of invasive microorganisms or ancestors. The cas gene, encoding the protein component of CRISPR system, flanks this region. Transcription and
processing of precursor crRNA produces mature crRNAs. The protein product of the cas gene is loaded with the crRNA, generating the effector complex. CRISPR pathway
activation results in DSBs at matching proto-spacer sequences included within invasive DNAs. This bacterial immunity response overcomes phage infection or exogenous
DNA invasion. (b) CRISPR/Cas9-catalyzed cleavage of target genomic DNA in cells. Schematic representation of target DNA and chimeric gRNA. The proto-spacer adjacent
motif (PAM) is an NGG sequence required for Cas9 recognition. Red triangles indicate cleavage sites. Cas9 opens the DNA duplex and cleaves both strands upon recognition
of a target sequence by the gRNA, but only if the correct PAM is present at the 30 end. (c) Schematic representation of CRISPR-based systems in action. Left panel, RNA-
guided targeting of genes in mammalian cells requires expression of Cas9 protein, modified with a nuclear localization sequence, and a gRNA targeting the genomic locus of
interest. The Cas9–gRNA effector complex identifies the targeting locus and excises the sequence from the genome. The central panel describes the CRISPRi system.
A defective Cas9 (*Cas9) lacks endonuclease activity. When coexpressed with a specific gRNA, *Cas9 recognizes the locus in genomic regulatory regions, specifically
interfering with transcriptional elongation, RNA polymerase binding or transcription factor binding. The CRISPRi system does not alter genomic sequences, but only interferes
with regulatory elements. The right panel provides an overview of CRISPR imaging. Imaging of genomic elements in living cells is possible by gRNA-directed defective
EGFP-fused Cas9. Sequence-specific enrichment of fluorescence signals can be measured by microscopy techniques. CMV, cytomegalovirus promoter; U6, U6-polymerase
III promoter
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agriculture and medicine. Indeed, if high-fidelity target recogni-
tion is confirmed, the biggest challenge ahead for CRISPR is to
correct human disease-associated mutations, finally providing
an effective gene therapy strategy for human genetic diseases.
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